Literature DB >> 29800044

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.

Valerie Cristina1, Jestinah Mahachie2, Murielle Mauer2, Thierry Buclin3, Eric Van Cutsem4, Arnaud Roth5,6, Anna D Wagner1,6.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29800044      PMCID： PMC6145725          DOI： 10.1001/jamaoncol.2018.1080

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients.

Authors:  Yuan Yuan; Lingxiang Liu; Hu Chen; Yumeng Wang; Yanxun Xu; Huzhang Mao; Jun Li; Gordon B Mills; Yongqian Shu; Liang Li; Han Liang
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

3.  Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

Authors:  Jackie Yao Liu; Kevin Qu; Anthony D Sferruzza; Richard A Bender
Journal:  Anticancer Drugs       Date:  2007-07       Impact factor: 2.248

4.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 5.  Sex differences in pharmacokinetics and pharmacodynamics.

Authors:  Monica Gandhi; Francesca Aweeka; Ruth M Greenblatt; Terrence F Blaschke
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

6.  An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.

Authors:  W Ichikawa; K Uehara; K Minamimura; C Tanaka; Y Takii; H Miyauchi; S Sadahiro; K Fujita; T Moriwaki; M Nakamura; T Takahashi; A Tsuji; K Shinozaki; S Morita; Y Ando; Y Okutani; M Sugihara; T Sugiyama; Y Ohashi; Y Sakata
Journal:  Br J Cancer       Date:  2015-04-16       Impact factor: 7.640
  6 in total
  13 in total

1.  Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial.

Authors:  Yasuhide Yamada; Kei Muro; Keiichi Takahashi; Hideo Baba; Yoshito Komatsu; Taroh Satoh; Masahiro Goto; Hideyuki Mishima; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Naruhito Takenaka; Tadashi Hirooka; Kenichi Sugihara
Journal:  Glob Health Med       Date:  2020-08-31

2.  Risk of cause-specific death, its sex and age differences, and life expectancy in post-pancreatitis diabetes mellitus.

Authors:  Jaelim Cho; Stephen J Pandol; Maxim S Petrov
Journal:  Acta Diabetol       Date:  2021-02-15       Impact factor: 4.087

3.  Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Authors:  Alper Okyar; Swati A Kumar; Elisabeth Filipski; Enza Piccolo; Narin Ozturk; Helena Xandri-Monje; Zeliha Pala; Kristin Abraham; Ana Rita Gato de Jesus Gomes; Mehmet N Orman; Xiao-Mei Li; Robert Dallmann; Francis Lévi; Annabelle Ballesta
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

4.  From presentation to paper: Gender disparities in oncological research.

Authors:  Willemieke P M Dijksterhuis; Charlotte I Stroes; Wan-Ling Tan; Suthinee Ithimakin; Antonio Calles; Martijn G H van Oijen; Rob H A Verhoeven; Jorge Barriuso; Sjoukje F Oosting; Daniela Kolarevic Ivankovic; Andrew J S Furness; Ivana Bozovic-Spasojevic; Carlos Gomez-Roca; Hanneke W M van Laarhoven
Journal:  Int J Cancer       Date:  2019-10-11       Impact factor: 7.396

5.  Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX.

Authors:  Jinkook Kim; Eunjeong Ji; Kwangrok Jung; In Ho Jung; Jaewoo Park; Jong-Chan Lee; Jin Won Kim; Jin-Hyeok Hwang; Jaihwan Kim
Journal:  J Pers Med       Date:  2021-01-30

Review 6.  Sex differences and sex bias in human circadian and sleep physiology research.

Authors:  Manuel Spitschan; Nayantara Santhi; Amrita Ahluwalia; Dorothee Fischer; Lilian Hunt; Natasha A Karp; Francis Lévi; Inés Pineda-Torra; Parisa Vidafar; Rhiannon White
Journal:  Elife       Date:  2022-02-18       Impact factor: 8.713

7.  Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.

Authors:  Anna D Wagner; Axel Grothey; Thierry Andre; Jesse G Dixon; Norman Wolmark; Daniel G Haller; Carmen J Allegra; Aimery de Gramont; Eric VanCutsem; Steven R Alberts; Thomas J George; Michael J O'Connell; Christopher Twelves; Julien Taieb; Leonard B Saltz; Charles D Blanke; Edoardo Francini; Rachel Kerr; Greg Yothers; Jean F Seitz; Silvia Marsoni; Richard M Goldberg; Qian Shi
Journal:  J Natl Cancer Inst       Date:  2021-04-06       Impact factor: 13.506

8.  Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.

Authors:  Anna Dorothea Wagner
Journal:  ESMO Open       Date:  2020-09

9.  Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study.

Authors:  Willemieke P M Dijksterhuis; Marianne C Kalff; Anna D Wagner; Rob H A Verhoeven; Valery E P P Lemmens; Martijn G H van Oijen; Suzanne S Gisbertz; Mark I van Berge Henegouwen; Hanneke W M van Laarhoven
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506

10.  Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.

Authors:  Joseph M Unger; Riha Vaidya; Kathy S Albain; Michael LeBlanc; Lori M Minasian; Carolyn C Gotay; N Lynn Henry; Michael J Fisch; Shing M Lee; Charles D Blanke; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2022-02-04       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.